伊妥木單抗，Iratumumab，CAS: 640735-09-7，AntibodySystem Laboratories

貨號：DHD80902

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75445.html

別名：MDX-060, CAS: 640735-09-7

簡介：

Iratumumab (MDX-060) 是一種人抗 CD30 的 IgG1κ 單克隆抗體。Iratumumab 抑制表達 CD30 的腫瘤細胞的生長。 Iratumumab 可用于霍奇金淋巴瘤 (HL) 和間變性大細胞淋巴瘤 (ALCL) 的研究。

貨號：DHD80902

產(chǎn)品品牌：Antibodysystem

通用名：Iratumumab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：MDX-060

靶點;物種：Human CD30/TNFRSF8

種類：Homo sapiens

受體鑒定：IgG1-kappa

CAS: 640735-09-7

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Immunotherapy in indolent Non-Hodgkin's Lymphoma. PMID: 35663281

Gateways to clinical trials. PMID: 19088949

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies. PMID: 33807678

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. PMID: 17335294

Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells. PMID: 29721369

MDX-060. Medarex. PMID: 16370393

Current treatment and immunotherapy of Hodgkin's lymphoma. PMID: 16330443

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. PMID: 19890373

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. PMID: 17515574